Latham & Watkins has advised Arcus Biosciences. Gunderson Dettmer has advised the underwriters. Arcus Biosciences, a clinical-stage, global biopharmaceutical company listed on the NYSE under the...
Arcus Biosciences Completes $287.5 Million Common Stock Offering
May Mobility’s $105 million Series D Financing Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented May Mobility in the transaction. May Mobility announced its $105 million Series D financing round, as part of its...
Star Therapeutics’ $90 Million Series C Financing Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Star Therapeutics in the transaction. Star Therapeutics announced its oversubscribed $90 million Series C financing to continue growth of its...
1KOMMA5°’s €215 Million Series B Financing Round
Osborne Clarke and Gunderson Dettmer advised G2 Venture Partners on its investment. 1KOMMA5° has raised €215 million in its Series B financing round. As a result,...
Arcus Biosciences’ $200 Million At-the-Market Offering
Gunderson Dettmer advised sales agents Goldman Sachs & Co. LLC and SVB Securities on the deal. Goldman Sachs & Co. LLC and SVB Securities acted as sales agents in...
Triana’s $110 Million Series A Financing
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Lightspeed Venture Partners on the deal while Mintz represented TRIANA Biomedicines. Lightspeed Venture Partners co-led the $110 million...
Neuron23’s $100 Million Series C Financing
Gunderson Dettmer represented Neuron23 on the deal. Neuron23, a biotechnology company, announced its $100 million Series C financing led by SoftBank Vision Fund 2. Neuron23 focuses on...
Electra Therapeutics’ $84 Million Series B Financing
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Electra Therapeutics on the deal. Electra Therapeutics, a clinical-stage biotechnology company, announced its $84 million Series B financing co-led...
Seismic Therapeutic’s $101 Million Series A Financing
Troutman Pepper advised Seismic Therapeutic, Inc. on the deal while Gunderson Dettmer represented Lightspeed Venture Partners. Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for...
Theseus Pharmaceuticals’ $160 Million IPO
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Theseus Pharmaceuticals on the deal. Theseus Pharmaceuticals, Inc., a biopharmaceutical company focused on improving the lives of cancer...